SP2509
| Code | Size | Price |
|---|
| SYN-1212-M100 | 100 mg | Enquire |
Quantity:
| SYN-1212-M050 | 50 mg | Enquire |
Quantity:
| SYN-1212-M001 | 1 mg | £151.00 |
Quantity:
| SYN-1212-M005 | 5 mg | £303.00 |
Quantity:
| SYN-1212-M010 | 10 mg | £467.00 |
Quantity:
Prices exclude any Taxes / VAT
Overview
Regulatory Status: RUO
Shipping:
-20°C
Documents
Further Information
Alternate Names/Synonyms:
SP-2509
Appearance:
Solid.
CAS:
1423715-09-6
EClass:
32160000
Form (Short):
liquid
InChi:
InChI=1S/C19H20ClN3O5S/c1-13(17-12-15(20)5-6-18(17)24)21-22-19(25)14-3-2-4-16(11-14)29(26,27)23-7-9-28-10-8-23/h2-6,11-12,24H,7-10H2,1H3,(H,22,25)/b21-13+
InChiKey:
NKUDGJUBIVEDTF-FYJGNVAPSA-N
Long Description:
Chemical. CAS: 1423715-09-6. Formula: C19H20ClN3O5S. MW: 437.9. LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi.
Molecular Formula:
C19H20ClN3O5S
Molecular Weight:
437.9
Package Type:
Plastic Vial
Product Description:
LSD1 is a promising target for cancer therapy. Epigenetic control of histone methylation is frequently associated with oncogenesis and LSD1 is overexpressed in many types of cancer. siRNA knockdown of LSD1 has been shown to suppress growth of cancer cells. SP-2528 is a selective and reversible LSD1 inhibitor with an IC(50) of 10nM. SP-2528 demonstrates a high specificity for LSD1, with no effect on MAOi.
Purity:
>95%
Solubility Chemicals:
Soluble in DMSO.
Transportation:
Non-hazardous
UNSPSC Category:
Protein Kinase Modulators
UNSPSC Number:
12352200
Use & Stability:
Stable for at least 2 years after receipt when stored at -20°C.
References
High-throughput virtual screening identifies novel N'-(1-phenylethylidene)-benzohydrazides as potent, specific, and reversible LSD1 inhibitors: V. Sorna, et al.; J. Med. Chem. 56 9496 (2013) | Highly effective combination of LSD1 (KDM1A) antagonist and pan-histone deacetylase inhibitor against human AML cells: W. Fiskus, et al.; Leukemia 28, 2155 (2014)
Related Products
| Product Name | Product Code | Supplier | GSK-J1 | SYN-3030 | AdipoGen Life Sciences | Summary Details | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|